outbreak
sarscov
influenza
measl
virus
recent
year
rais
seriou
concern
measur
avail
control
emerg
reemerg
infecti
viral
diseas
effect
antivir
agent
lack
specif
target
rna
virus
measl
sarscov
influenza
virus
avail
vaccin
demonstr
variabl
efficaci
therefor
develop
novel
antivir
agent
need
close
vaccin
gap
silenc
outbreak
previous
indentifi
mucroporin
cation
host
defens
peptid
scorpion
venom
effect
inhibit
standard
bacteria
optim
inhibit
gramposit
bacteria
low
concentr
antibioticresist
pathogen
investig
test
mucroporin
optim
antivir
activ
surprisingli
found
antivir
activ
measl
sarscov
influenza
virus
notabl
increas
ec
gml
cc
gml
measl
viru
ec
gml
sarscov
ec
gml
origin
peptid
mucroporin
show
antivir
activ
three
virus
inhibit
model
could
via
direct
interact
viru
envelop
therebi
decreas
infect
viru
report
provid
evid
host
defens
peptid
scorpion
venom
modifi
antivir
activ
ration
design
repres
practic
approach
develop
broadspectrum
antivir
agent
especi
rna
virus
rapidli
chang
global
landscap
local
environ
enorm
increas
human
popul
urban
mani
develop
countri
advanc
speed
volum
global
transport
creat
increas
opportun
emerg
reemerg
viral
diseas
virus
rna
genet
materi
quickli
adapt
exploit
variou
condit
high
genet
variat
rate
mutat
recombin
reassort
surprisingli
mani
promin
recent
exampl
emerg
reemerg
diseas
caus
rna
virus
sarscoronaviru
avian
influenza
virus
hiv
hantaviru
west
nile
viru
outbreak
measl
continu
still
lead
caus
morbid
mortal
children
worldwid
despit
avail
live
attenu
vaccin
year
effect
antivir
agent
lack
specif
target
rna
virus
measl
sarscov
influenza
current
avail
therapi
use
clinic
measl
viru
infect
treatment
administ
oral
intraven
alon
combin
immun
serum
globulin
demonstr
variabl
efficaci
side
effect
high
teratogen
anemia
mani
strategi
antisens
molecul
adenosin
guanosin
nucleosid
brassinosteroid
coumarin
peptid
inhibitor
modul
cholesterol
synthesi
also
fail
moreov
approv
univers
recommend
therapi
lack
sarscov
influenza
infect
even
though
antivir
agent
sarscov
influenza
report
therefor
develop
new
antivir
agent
need
provid
option
manag
case
diseas
caus
rna
virus
develop
develop
countri
cation
antimicrobi
peptid
amp
found
live
speci
potenti
broadspectrum
antivir
agent
scorpion
use
venom
weapon
subdu
prey
defend
predat
scorpion
venom
cocktail
peptid
protein
divers
bioactiv
thu
repres
unexplor
resourc
use
peptid
drug
design
develop
antimicrobi
peptid
scorpion
venom
attract
attent
due
potenti
applic
although
antibacteri
antifung
activ
amp
main
focu
studi
date
molecul
also
shown
effect
viral
pathogen
junin
viru
herp
simplex
viru
adenoviru
rotaviru
vaccinia
viru
hcv
hiv
mucroporin
first
cation
host
defens
peptid
venom
scorpion
lycha
mucronatu
clone
shown
exhibit
specif
effect
inhibit
bacteria
group
recent
found
mucroporin
effect
inhibit
standard
bacteria
especi
gramposit
bacteria
optim
design
amino
acid
substitut
result
inhibit
gramposit
bacteria
low
concentr
increas
inhibit
antibioticresist
pathogen
recent
also
found
novel
peptid
scorpion
venom
inhibit
hcv
replic
prevent
initi
hcv
infect
investig
test
mucroporin
optim
peptid
variant
bioactiv
includ
antivir
function
measl
sarscov
influenza
virus
surprisingli
found
virucid
activ
notabl
increas
wherea
origin
peptid
mucroporin
show
virucid
activ
result
report
indic
scorpion
venomderiv
antimicrobi
peptid
natur
resourc
inhibit
antibioticresist
bacteria
also
molecular
templat
design
antivir
peptid
antivir
agent
measl
sar
influenza
emerg
reemerg
rna
viral
diseas
mucroporin
acid
antimicrobi
peptid
venom
scorpion
lycha
mucronatu
recent
character
group
enhanc
net
posit
charg
hydrophil
side
design
substitut
glycin
prolin
residu
lysin
arginin
control
also
design
remov
sever
ntermin
amino
residu
mucroporin
mucroporin
lfglipsligglvsafk
lfrlikslikrlvsafk
ctermin
peptid
sligglvsafk
vsafk
correspond
residu
mucroporin
respect
synthes
abim
am
synthes
fmoc
solidphas
peptid
synthesi
peptid
ctermin
amid
peptid
deprotect
releas
resin
trifluoroacet
acid
tfa
treatment
precipit
cold
diethyl
ether
peptid
filter
millexhv
millipor
purifi
column
elitehplc
china
mm
mm
use
linear
gradient
h
tfa
min
constant
flow
rate
mlmin
peak
detect
absorb
nm
collect
manual
peptid
lyophil
puriti
assess
highperform
liquid
chromatographi
hplc
mass
spectrometri
vero
atcc
crl
mdck
obtain
american
type
cultur
collect
rockvil
md
cultur
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
penicillin
streptomycin
c
co
atmospher
hereaft
refer
growth
medium
dmem
supplement
fb
penicillin
streptomycin
use
viru
attach
refer
medium
edmonston
strain
measl
viru
mev
obtain
american
type
cultur
collect
propag
vero
cell
viru
titer
determin
plaqu
assay
also
vero
cell
use
pseudoviru
wildtyp
sarscov
pseudoviru
studi
produc
pseudoviru
egfp
report
cotransfect
cell
psvmomlvgagpol
plasmid
kindli
provid
dr
wang
wuhan
institut
virolog
chines
academi
scienc
ca
sarscov
pseudoviru
luciferas
assay
system
gener
cotransfect
plasmid
hivluc
cell
describ
previous
viru
titrat
mev
perform
plaqu
assay
briefli
vero
cell
monolay
plate
inocul
serial
dilut
mev
experiment
sampl
inoculum
replac
agaros
solut
mem
supplement
fb
absorpt
viru
h
cell
monolay
incub
c
day
fix
stain
formaldehyd
solut
crystal
violet
pb
h
room
temperatur
clear
plaqu
number
visual
viru
titer
plaqueform
unit
pfu
calcul
experi
done
triplic
repeat
least
three
time
test
peptid
antivir
effect
mev
follow
two
protocol
first
assay
inhibit
mev
plaqu
format
treat
pfuml
virus
serial
dilut
peptid
medium
incub
c
h
conduct
viru
plaqu
assay
describ
second
assay
suppress
mev
replic
pfuml
virus
treat
serial
dilut
peptid
medium
incub
c
h
subject
new
round
infect
vero
cell
monolay
final
assess
titer
newli
yield
viru
briefli
absorpt
viruspeptid
mixtur
vero
cell
h
inoculum
remov
fresh
growth
medium
ad
subsequ
cultur
h
cultur
supernat
cell
lysat
collect
freezethaw
three
time
centrifug
min
g
remov
cellular
debri
newli
yield
viru
titer
assess
plaqu
assay
experi
repeat
least
three
time
titrat
sarscov
pseudoviru
dilut
sarscov
pseudoviru
ad
cell
plate
h
c
replac
fresh
growth
medium
sixti
hour
later
cell
lyse
directli
plate
immedi
analyz
luciferas
activ
luciferas
assay
system
promega
madison
wi
modulu
tm
micropl
multimod
reader
sarscov
pseudoviru
titer
present
luciferas
rel
light
unit
rlu
assay
pseudoviru
dilut
pseudoviru
ad
mdck
cell
plate
h
c
inoculum
remov
replac
fresh
growth
medium
fortyeight
hour
later
egfp
fluoresc
express
infect
mdck
cell
examin
photograph
fluoresc
microscopi
number
fluoresc
cell
count
use
calcul
pseudoviru
titer
test
peptid
antivir
effect
sarscov
pseudoviru
pseudoviru
rluml
sarscov
pseudoviru
pfuml
pseudoviru
incub
serial
dilut
peptid
h
medium
subject
titer
assay
describ
antivir
effect
experi
sarscov
repeat
least
three
time
respect
vitro
cytotox
test
mucroporin
perform
tradit
tetrazolium
bromid
mtt
procedur
briefli
vero
cell
mdck
cell
cell
seed
plate
densiti
cellswel
incub
c
co
h
cultur
medium
replac
l
serial
dilut
peptid
cell
incub
h
l
sterilefilt
mtt
sigma
stock
solut
phosphat
buffer
salin
pb
ph
mgml
ad
well
h
unreact
dye
remov
aspir
insolubl
formazan
crystal
dissolv
lwell
isopropyl
alcohol
contain
moll
hcl
measur
spectrophotometr
elisa
reader
thermo
labsystem
wavelength
nm
posit
control
use
lysi
reagent
could
kill
cell
min
mean
absorb
subtract
test
rel
cell
viabil
relat
control
well
contain
cell
cultur
medium
without
peptid
calcul
test
control
cytotox
peptid
express
cytotox
concentr
cc
concentr
inhibit
growth
cell
rel
nontreat
control
cell
experi
repeat
least
three
time
analyz
inhibit
mevinfect
cell
determin
possibl
effect
viral
replic
cycl
vero
cell
monolay
plate
inocul
pfuml
mev
c
h
wash
three
time
serumfre
dmem
cell
treat
gml
differ
time
interv
h
h
h
h
pi
post
infect
infect
monolay
without
peptid
treatment
use
control
h
pi
infect
cell
harvest
yield
mev
analyz
plaqu
assay
experi
repeat
least
three
time
five
treatment
group
design
analysi
effect
mev
infect
vitro
vero
cell
pretreat
infect
mev
mev
mix
incub
h
mixtur
inocul
vero
cell
mev
mix
without
incub
mixtur
inocul
vero
cell
immedi
vero
cell
infect
mev
first
treat
control
vero
cell
infect
mev
without
treatment
compar
effect
viral
infect
gml
peptid
pfuml
mev
use
group
adsorpt
time
viru
peptid
treatment
time
h
group
cell
wash
three
time
serumfre
dmem
remov
unattach
viru
free
peptid
infect
treatment
inhibitori
effect
differ
group
analyz
plaqu
assay
experi
repeat
three
time
interact
measl
viru
peptid
perform
c
biacor
instrument
use
sensor
chip
ge
healthcar
life
scienc
peptid
attach
chip
surfac
follow
activ
surfac
carboxyl
group
use
mixtur
carbodiimid
hydrochlorid
edc
nhydroxysuccinimid
flow
rate
mlmin
peptid
dilut
sodium
acet
final
concentr
gml
ph
inject
manual
desir
level
respons
unit
ru
achiev
follow
attach
remain
surfac
carboxyl
group
quench
ml
ethanolamin
ph
flow
rate
mlmin
bind
experi
perform
hepesbuff
salin
solut
mm
hepe
ph
mm
nacl
mm
edta
c
flow
rate
lmin
aliquot
l
measl
viru
inject
onto
surfac
sensor
chip
flow
rate
lmin
sensor
chip
regener
success
inject
mm
sodium
hydroxid
respons
curv
subtract
background
signal
gener
refer
surfac
kinet
paramet
obtain
fit
sensorgram
langmuir
bind
model
use
biaevalu
softwar
experi
repeat
three
time
statist
analysi
done
oneway
anova
use
graphpad
prism
softwar
version
number
result
one
repres
least
three
time
repeat
experi
express
mean
standard
deviat
sd
three
repeat
sampl
statist
signific
test
set
p
lfrlikslikrlvsafk
design
base
protein
sequenc
mucroporin
enhanc
net
posit
charg
hydrophil
side
fig
glycin
prolin
residu
mucroporin
replac
lysin
arginin
contain
five
posit
charg
wherea
mucroporin
carri
one
posit
charg
fig
secondari
structur
mucroporin
peptid
predict
selfoptim
predict
method
sopm
websit
http
npsapbil
ibcpfrcgibinnpsa
automatpl
pagenpsanpsa
secconshtml
suggest
mucroporin
compos
respect
helix
divid
two
part
hydrophob
hydrophil
face
suggest
good
dipolar
molecul
design
remov
sever
ntermin
amino
residu
mucroporin
truncat
peptid
use
test
shorten
less
fig
peptid
sequenc
characterist
amino
acid
sequenc
align
mucroporin
ctermin
deriv
four
amino
acid
substitut
made
compar
mucroporin
sequenc
correspond
residu
mucroporin
respect
basic
polar
residu
shown
red
nonpolar
residu
indic
blue
mutat
residu
highlight
green
interpret
refer
color
figur
legend
reader
refer
web
version
articl
expens
peptid
biolog
activ
also
use
control
studi
mucroporin
ctermin
deriv
correspond
residu
mucroporin
fig
respect
success
synthes
abim
am
synthes
fmoc
solidphas
peptid
synthesi
puriti
four
peptid
show
reliabl
qualiti
follow
two
protocol
screen
peptid
quickli
antimev
activ
first
assay
inhibit
mev
plaqu
format
second
assay
suppress
mev
replic
protocol
use
treat
mev
mix
pfuml
mev
differ
concentr
mucroporin
incub
h
c
evalu
direct
effect
peptid
mev
infect
measur
plaqueform
unit
use
first
protocol
time
evalu
effect
peptid
mev
infect
measur
viral
abil
infect
cell
produc
viral
progeni
use
second
protocol
observ
similar
effect
peptid
mev
infect
protocol
fig
show
signific
inhibitori
effect
mev
infect
wherea
peptid
includ
mucroporin
show
antimev
activ
p
mev
infect
could
inhibit
almost
complet
gml
concentr
depend
fig
ec
valu
gml
tabl
antimev
activ
notabl
increas
compar
origin
peptid
mucroporin
p
determin
effect
time
need
act
mev
pfuml
mev
treat
gml
mucroporin
differ
time
viral
infect
examin
first
protocol
describ
fig
inhibitori
effect
peptid
mev
increas
longer
treatment
time
almost
inhibit
mev
infect
occur
min
treatment
antimev
activ
depend
peptid
concentr
treatment
time
altogeth
result
suggest
ration
design
peptid
inactiv
mev
inhibit
viral
replic
vitro
distinguish
select
antivir
activ
nonselect
cytotox
test
cytotox
peptid
mammalian
cultur
cell
vero
cell
monolay
treat
differ
concentr
peptid
h
viabil
cell
measur
use
mtt
assay
cc
valu
peptid
concentr
requir
reduc
cell
viabil
calcul
shown
tabl
cc
vero
cell
gml
almost
time
ec
valu
therefor
select
index
si
determin
relationship
peptid
antivir
activ
mev
replic
cycl
vero
cell
monolay
plate
infect
mev
treat
differ
time
interv
h
h
h
h
pi
result
reveal
minor
dif
fig
antimev
activ
mucroporin
data
repres
four
experi
show
averag
valu
three
parallel
well
express
percentag
viru
titer
rel
control
group
treat
without
peptid
error
bar
indic
standard
error
mean
mean
viru
titer
significantli
lower
p
cell
expos
peptid
mean
p
mean
p
inhibit
mev
plaqu
format
pfuml
virus
treat
gml
peptid
medium
incub
c
h
subject
directli
viru
plaqu
assay
b
suppress
mev
replic
pfuml
virus
treat
gml
peptid
medium
incub
c
h
subject
new
round
infect
vero
cell
monolay
newli
yield
viru
titer
assess
plaqu
assay
data
repres
three
experi
show
averag
valu
three
parallel
well
express
percentag
viru
titer
rel
control
group
treat
without
peptid
error
bar
indic
standard
error
mean
mean
viru
titer
significantli
lower
p
cell
expos
peptid
mean
p
mean
p
pfuml
virus
treat
differ
concentr
peptid
medium
incub
c
h
subject
directli
viru
plaqu
assay
group
treat
without
peptid
use
control
b
pfuml
virus
treat
gml
peptid
medium
differ
time
durat
directli
subject
viru
plaqu
assay
group
treat
without
peptid
correspond
treatment
time
durat
serv
control
ferenc
differ
treatment
show
inhibit
mev
infect
h
treatment
discern
inhibit
h
h
h
treatment
fig
therefor
viral
attach
peptid
unabl
interfer
follow
step
viru
replic
help
elucid
inhibit
mechan
vari
treatment
time
order
addit
group
mev
treat
directli
mix
togeth
incub
h
advanc
infect
cell
show
almost
inhibit
four
group
show
inhibit
fig
group
mev
mix
without
incub
group
vero
cell
pretreat
show
inhibit
conclud
experi
lethal
step
mev
occur
interact
directli
viru
particl
therebi
decreas
viru
infect
therefor
virucid
activ
mev
confirm
direct
interact
mev
particl
use
realtim
natur
biosensor
could
measur
peptidevir
particl
interact
made
serial
dilut
virus
hepe
buffer
aliquot
l
viru
inject
onto
surfac
sensor
chip
flow
rate
lmin
determin
associ
ka
dissoci
kd
constant
measl
viru
peptid
sensorgram
obtain
differ
concentr
virus
differ
peptid
bind
studi
use
langmuir
bind
model
biaevalu
softwar
analyz
bind
curv
obtain
peptideimmobil
flow
cell
viru
rel
associ
dissoci
constant
three
independ
experi
test
solut
summar
tabl
signal
reson
increas
dosedepend
manner
increas
viru
concentr
mev
significantli
higher
affin
mucroporin
indic
greater
associ
rate
constant
ka
fig
b
result
support
signific
specif
interact
mev
virucid
activ
mev
hypothes
may
broad
virucid
activ
virus
therefor
examin
effect
sarscov
virus
sarscov
influenza
pseudovirus
use
studi
best
safe
altern
present
incub
rluml
sarscov
pseudoviru
pfuml
pseudoviru
serial
dilut
h
medium
conduct
titer
assay
mucroporin
show
signific
inhibitori
effect
sarscov
pseudoviru
fig
pseudoviru
fig
c
concentrationdepend
manner
inde
gml
gml
could
almost
complet
inhibit
infect
sarscov
pseudoviru
pseudoviru
respect
fig
ec
valu
sarscov
pseudovirus
gml
gml
respect
meanwhil
cytotox
mdck
cell
also
conduct
cc
cell
mdck
cell
gml
gml
respect
thu
select
index
si
sarscov
pseudovirus
respect
therefor
possess
broadspectrum
virucid
activ
determin
effect
virucid
time
need
act
pseudovirus
differ
peptideviru
mixtur
incub
treat
time
test
effici
concentr
result
show
inhibitori
effect
pseudovirus
posit
correl
direct
treatment
time
inhibit
viru
infect
could
reach
min
data
shown
brief
scorpion
venom
peptid
variant
broadspectrum
virucid
activ
measl
sarscov
influenza
virus
result
suggest
ration
modif
scorpion
venom
peptid
may
chang
properti
peptid
endow
new
biolog
activ
despit
vaccin
measl
remain
burden
develop
develop
countri
current
use
antivir
treatment
mev
infect
limit
ribavirin
andor
immun
serum
globulin
show
variabl
efficaci
differ
mev
strain
furthermor
ic
valu
ribavirin
vari
vitro
therapeut
use
ribavirin
also
limit
side
effect
anemia
develop
novel
antivir
agent
need
close
vaccin
gap
treat
increas
outbreak
urg
us
test
scorpion
venomderiv
peptid
antimev
activ
previou
work
isol
differ
kind
cation
antimicrobi
peptid
cdna
librari
venom
gland
scorpion
identifi
potent
growthinhibitori
activ
antibioticresist
gramposit
pathogen
mucroporin
first
cation
host
defens
peptid
isol
venom
scorpion
lycha
mucronatu
recent
clone
demonstr
specif
effect
inhibit
bacteria
found
mucroporin
effect
inhibit
standard
bacteria
especi
gramposit
bacteria
moreov
optim
amino
acid
substitut
result
inhibit
gramposit
bacteria
low
concentr
inhibit
antibioticresist
pathogen
main
aim
investig
test
mucroporin
antivir
activ
found
antimev
activ
notabl
increas
molecular
modif
origin
peptid
mucroporin
show
antimev
activ
optim
modif
glycin
prolin
residu
mucroporin
replac
lysin
arginin
therebi
enhanc
net
posit
charg
hydrophil
side
chang
secondari
structur
peptid
modif
enabl
peptid
interact
directli
mev
particl
increas
affin
fig
antimev
activ
present
ec
valu
gml
origin
peptid
mucroporin
show
antimev
activ
moreov
found
could
also
inactiv
two
envelop
rna
virus
sar
cov
ec
gml
influenza
ec
gml
although
select
index
si
sarscov
pseudovirus
show
big
divers
respect
result
provid
evid
host
defens
peptid
scorpion
modifi
antivir
activ
ration
design
repres
templat
approach
develop
broadspectrum
antivir
agent
molecular
design
antivir
peptid
becom
import
attract
strategi
develop
new
antivir
drug
viral
entri
earli
key
stage
viral
infect
mani
antivir
peptid
design
target
viru
cell
interact
competit
fusion
inhibitor
base
templat
interact
domain
viral
ligand
cellular
receptor
one
particular
exampl
ration
drug
design
enfuvirtid
fusion
inhibitor
function
ml
pseudoviru
incub
serial
dilut
mucroporin
h
medium
subject
titer
assay
group
treat
without
peptid
use
control
data
repres
three
experi
show
averag
valu
three
parallel
well
express
percentag
viru
titer
rel
control
group
error
bar
indic
standard
error
mean
mean
viru
titer
significantli
lower
p
cell
expos
peptid
mean
p
mean
p
c
fluoresc
microscopi
mdck
cell
infect
peptidetr
untreat
pseudoviru
pseudovirus
incub
serial
dilut
mucroporin
h
ad
mdck
cell
examin
infecti
abil
upper
left
panel
display
mdck
monolay
cell
light
microscopi
middl
left
panel
show
untreat
control
group
lower
left
panel
show
group
treat
gml
mucroporin
right
panel
show
group
treat
differ
concentr
bar
disrupt
molecular
machineri
final
stage
fusion
target
cell
therebi
prevent
uninfect
cell
becom
infect
recent
amp
natur
resourc
attract
attent
molecul
shown
effect
viral
pathogen
peptid
produc
enterococcu
mundtii
isol
soya
bean
show
broadspectrum
antivir
activ
herp
simplex
virus
polio
viru
measl
viru
addit
antibacteri
activ
natur
resourc
screen
potenti
antivir
activ
scorpion
venom
cocktail
peptid
protein
divers
special
bioactiv
thu
repres
unexplor
resourc
use
drug
design
develop
believ
scorpion
venom
also
valuabl
resourc
antivir
drug
develop
tri
test
origin
molecular
templat
mucroporin
antimev
activ
found
also
inactiv
two
envelop
rna
virus
sarscov
influenza
mucroporin
report
kill
pathogen
break
bacteri
membran
antimeasl
viru
activ
glycin
prolin
residu
mucroporin
replac
lysin
arginin
result
net
posit
charg
hydrophil
side
could
inactiv
mev
effect
inactiv
mev
enhanc
concentr
treat
time
increas
reveal
mechan
action
least
partli
due
direct
interact
measl
viru
surfac
studi
relationship
peptid
inhibit
mev
replic
cycl
suggest
viral
attach
step
achiev
peptid
unabl
interfer
follow
step
viru
replic
experi
test
variou
treatment
time
order
addit
reveal
mev
treatment
mix
togeth
incub
h
advanc
infect
cell
show
effect
inhibit
taken
togeth
specul
inhibit
mev
sarscov
influenza
direct
virucid
action
may
bind
viru
envelop
surfac
charg
interact
drastic
decreas
infect
three
virus
howev
mucroporin
inhibitori
activ
vaccinia
viru
envelop
dna
viru
data
shown
therefor
whether
function
viral
surfac
protein
surfac
lipid
need
investig
summari
identifi
ration
design
scorpion
venom
peptid
variant
describ
dual
antimicrobi
activ
virus
bacteria
may
consid
lead
compound
treat
coinfect
virus
bacteria
peptid
dual
antimicrobi
activ
also
consid
good
addit
antisept
mouthwash
handwash
discoveri
bioactiv
suggest
cation
host
defens
peptid
scorpion
venom
might
good
templat
antivir
peptid
design
show
potenti
multifunct
antivir
agent
